blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3080119

EP3080119 - TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.05.2021
Database last updated on 13.07.2024
FormerThe patent has been granted
Status updated on  05.06.2020
FormerGrant of patent is intended
Status updated on  11.02.2020
FormerExamination is in progress
Status updated on  30.06.2017
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): BE		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
UCB Biopharma SRL
Allée de la Recherche 60
1070 Brussels / BE
[2020/28]
Former [2020/02]For all designated states
UCB Biopharma SRL
Allé de la Recherche 60
1070 Brussels / BE
Former [2016/42]For all designated states
UCB Biopharma SPRL
Allée de la Recherche 60
1070 Brussels / BE
Inventor(s)01 / JACKSON, Victoria Elizabeth
c/o IPD
UCB CELLTECH
208 Bath Road
Slough Berkshire SL1 3WE / GB
02 / KROEPLIEN, Boris
c/o IPD
UCB CELLTECH
208 Bath Road
Slough Berkshire SL1 3WE / GB
03 / LOWE, Martin Alexander
c/o IPD
UCB CELLTECH
208 Bath Road
Slough Berkshire SL1 3WE / GB
04 / PORTER, John Robert
c/o IPD
UCB CELLTECH
208 Bath Road
Slough Berkshire SL1 3WE / GB
 [2016/42]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2020/28]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2016/42]Duckworth, Timothy John
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date14811827.608.12.2014
[2016/42]
WO2014EP76875
Priority number, dateGB2013002174909.12.2013         Original published format: GB 201321749
[2016/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015086521
Date:18.06.2015
Language:EN
[2015/24]
Type: A1 Application with search report 
No.:EP3080119
Date:19.10.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 18.06.2015 takes the place of the publication of the European patent application.
[2016/42]
Type: B1 Patent specification 
No.:EP3080119
Date:08.07.2020
Language:EN
[2020/28]
Search report(s)International search report - published on:EP18.06.2015
ClassificationIPC:C07D471/04, A61K31/437, A61P29/00
[2016/42]
CPC:
C07D471/04 (EP,RU,US); A61K31/437 (EP,RU,US); A61P25/00 (EP);
A61P25/04 (EP); A61P25/28 (EP,RU); A61P27/00 (EP,RU);
A61P27/02 (EP); A61P29/00 (EP,RU); A61P29/02 (EP);
A61P3/00 (EP,RU); A61P35/00 (EP,RU); A61P37/00 (EP,RU);
A61P37/02 (EP); A61P43/00 (EP); A61P9/00 (EP,RU) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/42]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:TETRAHYDROIMIDAZOPYRIDINDERIVATE ALS MODULATOREN DER TNF-AKTIVITÄT[2016/42]
English:TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY[2016/42]
French:DÉRIVÉS DE TÉTRAHYDROIMIDAZOPYRIDINE COMME MODULATEURS DE L'ACTIVITÉ DU TNF[2016/42]
Entry into regional phase04.07.2016National basic fee paid 
04.07.2016Designation fee(s) paid 
04.07.2016Examination fee paid 
Examination procedure04.07.2016Amendment by applicant (claims and/or description)
04.07.2016Examination requested  [2016/42]
30.06.2017Despatch of a communication from the examining division (Time limit: M06)
22.12.2017Reply to a communication from the examining division
16.04.2018Despatch of a communication from the examining division (Time limit: M06)
17.10.2018Reply to a communication from the examining division
30.01.2019Despatch of a communication from the examining division (Time limit: M06)
02.08.2019Reply to a communication from the examining division
12.02.2020Communication of intention to grant the patent
01.06.2020Fee for grant paid
01.06.2020Fee for publishing/printing paid
01.06.2020Receipt of the translation of the claim(s)
Opposition(s)09.04.2021No opposition filed within time limit [2021/24]
Fees paidRenewal fee
20.04.2017Renewal fee patent year 03
12.12.2017Renewal fee patent year 04
12.12.2018Renewal fee patent year 05
13.12.2019Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.12.201603   M06   Fee paid on   20.04.2017
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.12.2014
AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
MT08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
IE08.12.2020
LU08.12.2020
BE31.12.2020
[2022/33]
Former [2022/32]HU08.12.2014
AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
MT08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
IE08.12.2020
LU08.12.2020
Former [2022/28]HU08.12.2014
AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
MT08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
IE08.12.2020
LU08.12.2020
Former [2021/47]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
IE08.12.2020
LU08.12.2020
Former [2021/46]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
IE08.12.2020
Former [2021/40]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/36]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/28]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/25]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/22]AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/21]AT08.07.2020
DK08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
NL08.07.2020
PL08.07.2020
RS08.07.2020
SE08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/17]AT08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
NL08.07.2020
PL08.07.2020
RS08.07.2020
SE08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/10]AT08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
PL08.07.2020
RS08.07.2020
SE08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/09]AT08.07.2020
FI08.07.2020
LT08.07.2020
SE08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
PT09.11.2020
Former [2021/08]FI08.07.2020
LT08.07.2020
SE08.07.2020
BG08.10.2020
NO08.10.2020
PT09.11.2020
Former [2021/07]FI08.07.2020
LT08.07.2020
NO08.10.2020
Cited inInternational search[X]EP0531874  (TANABE SEIYAKU CO [JP]) [X] 1-5 * claim 1 and examples *;
 [X]EP0682023  (TANABE SEIYAKU CO [JP]) [X] 1-5 * claim 1 and examples *;
 [X]JP2000256286  (KAKEN PHARMA CO LTD) [X] 1-4,7-15 * compound 89, p. 14; abstract *;
 [X]WO0200655  (DU PONT PHARM CO [US]) [X] 1-3,7-15 * claim 2; 4 first formulas in p. 185 and A-B as in p. 186-193; page 143, lines 3-14 *;
 [X]WO03084954  (PFIZER LTD [GB], et al) [X] 1,5,7-15 * claim 1, examples 1-28, 38-43, preparation 9-14, 16-28; page 1, lines 5-27 *;
 [XA]WO2004064778  (MERCK & CO INC [US], et al) [X] 1-5,7-15 * claim 1, compounds 30 and 42; p. 30 l. 29- p. 35, 8 * [A] 6;
 [X]WO2007066201  (PFIZER LTD [GB], et al) [X] 1,5,7-15 * claim 1, examples 1-69, 132-134; preparations 4-6; page 1, lines 4-8 *;
 [X]WO2010021381  (TAKEDA PHARMACEUTICAL [JP], et al) [X] 1,7-15 * abstract, claim 1, compounds in par. [0198], [0345] and p. 186 compounds 70-77 and 87. *;
 [X]WO2010114971  (SEPRACOR INC [US], et al) [X] 1-4,7-15* claim 1, compounds 111.6-111.8; par. [004]-[008] *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.